Dr Agarwals Eye Hospital Reports Strong Annual Performance

Annual Total Revenue: ₹476.69 Crores
Standalone Profit After Tax: ₹70.10 Crores

Reader Takeaway: Solid annual growth drivers include increased revenue and profitability, but quarterly profit growth was modest.

What Happened

Dr Agarwals Eye Hospital Ltd announced its financial results for the quarter and year ended March 31, 2026. For the full year, the company reported standalone total revenue of ₹476.69 Crores, an 18.51% increase from ₹402.24 Crores in the previous year. Standalone Profit After Tax (PAT) grew by 28.27% to ₹70.10 Crores from ₹54.66 Crores. Basic Earnings Per Share (EPS) for the year stood at ₹147.02.

On a quarterly basis, for the three months ended March 31, 2026, standalone total revenue was ₹121.58 Crores, a 21.67% rise year-on-year from ₹99.93 Crores. However, quarterly PAT saw a more modest increase of 1.56%, reaching ₹16.24 Crores compared to ₹15.99 Crores in the same period last year. Basic EPS for the quarter was ₹33.60.

Why This Matters

The strong annual performance signals healthy business expansion and improved operational efficiency. The significant increase in net profit, outpacing revenue growth, suggests effective cost management. The strengthening of the balance sheet through a preferential issue and debt reduction provides financial stability and flexibility for future growth.

The Backstory

In the previous fiscal year (ended March 31, 2025), Dr Agarwals Eye Hospital had reported annual revenue of ₹402.24 Crores and a net profit of ₹54.66 Crores. As of March 31, 2025, the company had total equity of ₹209.61 Crores and non-current borrowings of ₹81.77 Crores.

What Changes Now

Following the positive financial results and a recommended dividend of ₹7.00 per share, investors may anticipate stock price appreciation. The strengthened balance sheet could enable future expansion plans. However, the ongoing proposed amalgamation with the holding company, AHCL, remains a key event to monitor for further structural changes.

Risks to Watch

Investors should note the uncertainty surrounding the proposed amalgamation with AHCL, which is pending regulatory and shareholder approvals. Additionally, the significantly slower profit growth on a quarterly basis compared to the annual growth warrants attention.

Context Metrics

• Annual Revenue Growth (YoY): 18.51%
• Annual Profit Growth (YoY): 28.27%
• Quarterly Revenue Growth (YoY): 21.67%
• Quarterly Profit Growth (YoY): 1.56%
• Preferential Issue: ₹70 Crores raised
• Debt Reduction (Non-current borrowings): ₹81.77 Cr to ₹67.14 Cr
• Dividend Recommended: ₹7.00 per share

What to Track Next

Investors should closely monitor the progress of the amalgamation with AHCL and any updates on regulatory and shareholder approvals. Continued strong quarterly performance will be key to sustaining investor confidence.